医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): A biomarker-stratified, randomised phase 3 trial

广告
第一作者: Gregorc,V.
作者单位: Biodesix, Boulder, CO, United States [1] Università Vita-Salute San Raffaele, School of Medicine, Department of Pathology, Istituto di [2] Division of Medical Oncology, Department of Medical Oncology, Azienda Ospedaliera Treviglio [3] Lung Cancer Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera [4] Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy [5] Department of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico-Istituto di Richerche [6] Department of Oncology, University of Turin, Azienda Ospedaliera Universitaria San Luigi Orbassano [7] Department of Medical Oncology, National Cancer Institute of Aviano, Aviano, Italy [8] Oncology Unit, Villa Scassi Hospital, Azienda Sanitaria Locale 3, Genoa, Italy [9] Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale San [10] Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy, 1st Oncological [11] Division of Medical Oncology, Centro di Riferimento Oncologico di Basilicata, Istituto di Ricovero [12]
发布时间 2014-07-31
提交
  • 浏览2
The lancet oncology

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷